ARTICLE | Clinical News
Inovelon rufinamide regulatory update
July 16, 2012 7:00 AM UTC
Swissmedic approved Inovelon rufinamide orange-flavored oral suspension as an adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients >4 years. Eisai already markets...